Lymphoma Clinical Trials in Minneapolis

Showing 241-260 of 506 trials

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

NCT01696461

This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.

Center for International Blood and Marrow Transplant Research127 participantsStarted May 2013

Tampa, Florida, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +9 more locations

TERMINATEDPhase 2< 1 mile

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00335140

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.

Lymphoma

Eastern Cooperative Oncology Group26 participantsStarted Aug 2007

Stanford, California, United States • Gainesville, Florida, United States • Jacksonville, Florida, United States +65 more locations

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Lymphoma Trials in Other Cities

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

Safety Study of SEA-CD40 in Cancer Patients

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Bortezomib in Treating Patients With Mantle Cell Lymphoma

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Other Conditions in Minneapolis